首页> 外文OA文献 >Optimized Parameters of Diffusion-Weighted MRI for Prediction of the Response to Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer
【2h】

Optimized Parameters of Diffusion-Weighted MRI for Prediction of the Response to Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer

机译:扩散加权MRI的优化参数,用于预测Neoadjuvant ChemoRAdiotapy治疗局部晚肠癌的响应

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Aim. To identify the optimal diffusion-weighted MRI-derived parameters for predicting the response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. Methods. This prospective study enrolled 92 patients who underwent neoadjuvant chemoradiotherapy. Diffusion-weighted MRI sequences with two b-value combinations of b (0, 800) and b (0, 1000) were acquired before the start of neoadjuvant chemoradiotherapy and surgery. The pathological tumor regression grade was obtained according to the Mandard criteria, recommended by the seventh edition of the American Joint Committee on Cancer, to act as the reference standard. Pathological good responders (pathological tumor regression grade 1-2) were compared with poor responders (pathological tumor regression grade 3–5). Results. The good responder group contained 37 (40.2%) patients and the poor responder group 55 (59.8%) patients. Both before and after neoadjuvant chemoradiotherapy, the mean ADC value for b = 1000 was significantly higher than that for b = 800. In the two patient groups, the post-ADC value and ΔADC for b = 800 were significantly lower than those for b = 1000, but percentages of ADC increase for b = 800 and b = 1000 showed no significant difference. Conclusions. The percentage of ADC increase, as an optimized predictor unaffected by different b-values, may have a significant role in differentiating those patients with a good response to N-CRT from those with a poor response.
机译:目的。鉴定最佳扩散加权MRI衍生参数,以预测局部晚肠癌对新辅助化学疗法的响应。方法。该前瞻性研究招收了92名接受新辅助化学疗法的患者。在Neoadjuvant ChemoRadioCherapy和手术开始之前,在新辅助化学疗法和手术开始之前获得具有B(0,800)和B(0,1000)的两个B值组合的扩散加权MRI序列。病理肿瘤回归等级根据曼德州的标准获得,由美国联合癌症委员会第七版推荐,作为参考标准。将病理良好响应者(病理肿瘤回归级1-2)与贫患者(病理肿瘤回归级3-5)进行比较。结果。良好的响应者组含有37例(40.2%)患者和贫困症群55(59.8%)患者。在Neoadjuvant ChemorAdiotapia治疗之前和之后,B = 1000的平均ADC值显着高于B = 800.在两个患者组中,B = 800的后ADC值和ΔAdc显着低于B = 1000,但B = 800和B = 1000增加ADC增加的百分比显示没有显着差异。结论。 ADC增加的百分比,作为不受不同B值不受影响的优化预测因子,可能在区分那些对来自反应差的患者的患者对N-CRT的良好反应具有重要作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号